Myelofibrosis Clinical Trials

Find Myelofibrosis Clinical Trials Near You

An Exploratory Study of Gecacitinib in the Peri-Transplant Period for Patients With Myeloid Neoplasms and Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

This is a single-arm, single-center exploratory study evaluating the safety and efficacy of gecacitinib administered in the peri-transplant period in patients with myeloid neoplasms and myelofibrosis (MF) who are scheduled to undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT).Approximately 10 eligible patients will receive oral gecacitinib starting 13 weeks before transplantation. Treatment will continue through the peri-transplant period and for up to 24 weeks after hematopoietic reconstitution. The primary endpoint is the engraftment rate at day +28 post-transplant. Secondary endpoints include poor graft function rate, grade III-IV acute GVHD rate, overall survival, infection rate, and bone marrow fibrosis grade changes.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients must voluntarily sign the informed consent form, be aged ≥18 years at the time of informed consent, and may be of either sex.

• Diagnosed with myeloid neoplasms according to 2022 WHO diagnostic criteria

• Bone marrow fibrosis grade ≥2 according to 2016 WHO myelofibrosis grading criteria

• Undergoing first allogeneic hematopoietic stem cell transplantation

• ECOG performance status: 0-2

• Able to swallow tablets

• Able to comply with study procedures and follow-up requirements

Locations
Other Locations
China
No. 197, Ruijin Second Road, Shanghai
RECRUITING
Shanghai
Contact Information
Primary
Zilu Zhang, PhD
zzl12402@rjh.com.cn
021-64370045
Time Frame
Start Date: 2026-10-15
Estimated Completion Date: 2029-09-30
Participants
Target number of participants: 10
Treatments
Experimental: Experimental: gecacitinib Peri-Transplant
gecacitinib is administered orally, starting 13 weeks before allo-HSCT. Starting dose is based on baseline platelet count: 100 mg twice daily (BID) if platelets ≥50×10\^9/L, or 50 mg BID if platelets \<50×10\^9/L.The dose will be reduced to 50 mg BID beginning on day -7 (1 week before transplantation) and maintained at this dose during conditioning and transplantation. After hematopoietic reconstitution (PLT ≥50×10\^9/L and ANC ≥0.5×10\^9/L), the dose is increased to 100 mg BID for 12 weeks, then tapered to 50 mg BID for another 12 weeks before discontinuation.
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital

This content was sourced from clinicaltrials.gov